Skip to main content

Advertisement

Log in

Efficacy of carvacryl acetate in vitro and following oral administration to mice harboring either prepatent or patent Schistosoma mansoni infections

  • Helminthology - Original Paper
  • Published:
Parasitology Research Aims and scope Submit manuscript

Abstract

Schistosomiasis is a major public health problem that afflicts more than 240 million individuals globally, particularly in poor communities. Treatment of schistosomiasis relies heavily on a single oral drug, praziquantel, and there is interest in the search for new antischistosomal drugs. This study reports the anthelmintic evaluation of carvacryl acetate, a derivative of the terpene carvacrol, against Schistosoma mansoni ex vivo and in a schistosomiasis animal model harboring either adult (patent infection) or juvenile (prepatent infection) parasites. For comparison, data obtained with gold standard antischistosomal drug praziquantel are also presented. Initially in vitro effective concentrations of 50% (EC50) and 90% (EC90) were determined against larval and adult stages of S. mansoni. In an animal with patent infection, a single oral dose of carvacryl acetate (100, 200, or 400 mg/kg) caused a significant reduction in worm burden (30–40%). S. mansoni egg production, a process responsible for both life cycle and pathogenesis, was also markedly reduced (70–80%). Similar to praziquantel, carvacryl acetate 400 mg/kg had low efficacy in pre-patent infection. In tandem, although carvacryl acetate had interesting in vitro schistosomicidal activity, the compound exhibited low efficacy in terms of reduction of worm load in S. mansoni-infected mice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

Download references

Acknowledgements

We are grateful to Dr. Daniel B. Roquini and Marcos P. Silva (Núcleo de Pesquisa em Doenças Negligenciadas, Universidade Guarulhos, Brazil) for support during in vitro and in vivo studies and Dr. Aparecida R dos Santos (Ecovet Industria Veterinaria Ltda, São Paulo, SP, Brazil) for donation of praziquantel. We also thank to Dra Suzana A. Z. Lescano (Instituto de Medicina Tropical, Universidade de São Paulo, Brazil) for her support during in vivo experiments.

Funding

This work was supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), grant number 2016/22488–3. ACM and VCR were supported by a fellowship from the FAPESP (grant 2019/25905–2 and grant 2019/25289–0). BCS received a scholarship from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (PROSUP/CAPES). The funding institutions had not any role in study design, data collection, data analysis, interpretation, or writing of the report in this study.

Author information

Authors and Affiliations

Authors

Contributions

BCS and JM: Conceptualization. BCS, ACM, VCR, RAC, PUC, and CSMBF: Methodology. ACM and JM: Software. ACM, VCR, and RAC: Validation. BCS and ACM: Formal analysis. BCS, ACM, VCR, and RAC: Investigation. MCCES, DPS, and JM: Resources. ACM and VCR: Data curation. BCS and ACM: Writing—original draft preparation. JM: Writing—review and editing. BCS, ACM, VCR, RAC, PUC, MCCES, CSMBF, DPS, and JM: Visualization. ACM: Supervision. JM: Project administration. JM: Funding acquisition. All authors have read and agreed to the published version of the manuscript.

Corresponding author

Correspondence to Josué de Moraes.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Section Editor: Christoph G. Grevelding

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 16 kb) Method of obtaining carvacryl acetate and NMR data.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Silva, B.C., Mengarda, A.C., Rodrigues, V.C. et al. Efficacy of carvacryl acetate in vitro and following oral administration to mice harboring either prepatent or patent Schistosoma mansoni infections. Parasitol Res 120, 3837–3844 (2021). https://doi.org/10.1007/s00436-021-07333-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00436-021-07333-2

Keywords

Navigation